Neuralink, a brain implant company is valued at $5 billion which was revealed by privately executed stock trades described to a news channel. It was valued at $2 billion in a private fundraising round two years ago.

Highlights

• Neuralink could take years to secure commercial use clearance
• In recent days Neuralink shares were marketed privately to investors
• A more modest and short-term objective was given by a Neuralink executive

Working on brain implantation, Elon Musk’s company Neuralink gained more attention in two years when its shares went to private investors and news channels pickup for circulation. The current valuation of companies is $5 billion as told by privately executed stock trades.

The surge in the valuation of Neuralink was recorded in recent months when some bullish of the market purchased the stock of Neuralink after the U.S. regulators approved a human mind trial for the Neuralink Company and to trial for its brain chip trial. The information was revealed as per the sources.

As per some of the experts, Neuralink’s objective of implanting its brain may take several years to secure commercial use clearance. As per the former program director for neural engineering at the U.S.  National Institute of Health (NIH) Kip Ludwig, the company “optimistically” will take at least 10 years more to make its brain implant commercialized in the world. At present the company is facing some other challenges as well like probing by federal authorities related to its handling of animal research.

We can see the jump in shares of Neuralink in secondary trades that were sharper than other startups. As per the reports, more than 85 percent of pre-IPO companies are currently valued in secondary trades at an average discount.

Hiive which is an online platform where shares are traded, said the CEO Sim Desai the demand for the Neuralink shares has been high and currently the buyers are willing to pay around $4.5 billion.